Tonix Pharmaceuticals Holding TNXP

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. The company’s portfolio includes commercial products and a broad pipeline of development-stage candidates spanning multiple therapeutic areas. Tonix Pharmaceuticals Holding Corp has established commercial operations and is advancing its pipeline through internal discovery, in-licensing, acquisitions, and collaborations with academic and non-profit institutions.

Tonix Pharmaceuticals Holding Corp generates revenue primarily from the sale of its FDA-approved commercial products. These include TONMYA for the treatment of fibromyalgia in adults, and Zembrace SymTouch and Tosymra for the acute treatment of migraine with or without aura in adults. The company markets these products through its sales organization, which comprises an internal sales force, contracted sales representatives, and support functions such as market access, patient services, and distribution via national wholesalers and specialty distributors. Revenue is derived from product sales to healthcare providers and payers, with efforts focused on securing formulary coverage and driving adoption among prescribers in rheumatology, primary care, pain management, and neurology practices.

Tonix Pharmaceuticals Holding Corp operates through the following segments: Central Nervous System, Immunology and Infectious Disease, and Rare Disease.

• The Central Nervous System segment includes the development and commercialization of therapies for fibromyalgia, major depressive disorder, acute stress reaction and disorder, post-traumatic stress disorder, agitation in Alzheimer’s disease, alcohol use disorder, multi-site pain associated with Long COVID, binge eating disorder, adolescent obesity, bone health in pediatric autism, arginine-vasopressin deficiency, and cocaine intoxication. Key product candidates in this segment are TNX-102 SL (sublingual cyclobenzaprine) for multiple indications, TNX-1300 for cocaine intoxication, and TNX-1900 for various neuropsychiatric and metabolic conditions.
• The Immunology and Infectious Disease segment focuses on preventing organ transplant rejection, treating autoimmune diseases, and developing prophylactics and therapeutics for infectious diseases. Programs in this segment include TNX-1500 for kidney transplant rejection and autoimmune conditions, TNX-4800 for seasonal prevention of Lyme disease, TNX-801 as a live virus vaccine for smallpox and mpox, TNX-4200 as a broad-spectrum antiviral targeting CD45, and TNX-1700 for gastric and colorectal cancer in combination with PD-1 blockade.
• The Rare Disease segment is dedicated to developing treatments for Prader-Willi syndrome. The lead candidate in this segment is TNX-2900, an intranasal oxytocin formulation potentiated with magnesium, which has received Orphan Drug and Rare Pediatric Disease designations from the FDA and is advancing toward a Phase 2 clinical trial.

Tonix Pharmaceuticals Holding Corp operates in highly competitive therapeutic areas where it faces numerous large pharmaceutical and biotechnology companies. In fibromyalgia, the company competes with established treatments such as pregabalin, duloxetine, and milnacipran, and is positioning TONMYA as a novel therapy targeting non-restorative sleep. In migraine, Zembrace SymTouch and Tosymra compete with generic sumatriptan formulations and newer agents like oral and intranasal CGRP antagonists. The company’s competitive advantages stem from its differentiated product mechanisms, such as the transmucosal delivery of TNX-102 SL to reduce active metabolite exposure, and its strategic focus on underserved indications with high unmet medical need, including Lyme disease prophylaxis and cocaine intoxication, where few or no approved therapies exist.

Tonix Pharmaceuticals Holding Corp serves healthcare providers and patients across its commercial products. The company sells TONMYA, Zembrace SymTouch, and Tosymra through national pharmaceutical wholesalers, specialty distributors, pharmacies, and healthcare institutions. Its products are prescribed by physicians in specialties such as rheumatology, primary care, pain management, and neurology for fibromyalgia, and by healthcare providers treating acute migraine in adults. The company supports patient access through market access programs and patient assistance services to facilitate therapy initiation and continuation.